Inspire Medical Systems (INSP) investor relations material

Coding and reimbursement updates

• Clear coding pathways established for Medicare, commercial, and Medicare Advantage, with ongoing education for centers and physicians to ensure reimbursement confidence.

• Payment levels for facilities and physicians remain consistent with 2025, with minor variations due to modifiers.

• Two of seven Medicare MACs require a -52 modifier, resulting in a 10%-20% reduction in physician payment; others may follow, but tools are in place to adapt.

• A new CPT code application was submitted to the AMA for review in September 2026, aiming for implementation by January 2028.

• WISeR program implementation in six states is improving, with initial headwinds expected to lessen throughout the year.

Technology and product innovation

• Inspire V system launched with closed-loop sensing, improving synchronization of stimulation to 87.1% of breaths and eliminating the need for a respiratory sensor.

• SleepSync platform enhancements allow digital prior authorization requests, streamlining administrative processes for centers.

• Inspire VI is in development, focusing on auto-activation and sleep detection to further improve therapy adherence.

• Remote programming for SleepSync is under development, with no set release date yet.

Clinical evidence and outcomes

• ADHERE registry of 5,000 patients shows median Apnea-Hypopnea Index reduction from 32 to 10 and 90% patient satisfaction.

• Therapy adherence averages 5.8–6.4 hours per night, with most patients not requiring sleep endoscopy based on new PREDICTOR algorithm.

• New data links Inspire therapy to significant reductions in hypoxic burden, correlating with improved cardiovascular health.

• Large real-world studies show Inspire associated with lower risk of heart failure, coronary artery disease, and cardiomyopathy compared to CPAP and no treatment.